Glenmark's current portfolio consists of 174 products authorized for distribution in the U.S. marketplace and 48 ANDA's pending approval with the USFDA
The plan is to advance innovative therapies to drug-resistant cancers
SCG101 is an autologous T-cell receptor (TCR) T-cell therapy for liver cancer
Novel approach driven by GN Corp Japan with potentials in neurological illnesses
The investigational prescription digital therapeutic uses a combination of sensors, software, and music based on Rhythmic Auditory Stimulation (RAS)
The EBUS is designed to support the diagnosis and staging of various lung disorders
CLNK is a biotechnology research and development company that utilizes umbilical cord blood as the raw material to develop innovative, allogeneic, off-the-shelf, cell based therapeutic products
Funds will be allocated to accelerate rapid production and high-end curation of whole genome sequences for its clinical application
Flagship U.S. facility will include biologic manufacturing and late stage research and clinical development of innovative cancer medicines
Center of Excellence for Molecular Diagnostics and Proteomics will enable affordable diagnostics for infectious diseases in India
Subscribe To Our Newsletter & Stay Updated
